Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

EP: 1.Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP: 2.Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP: 3.Outcomes from NATALEE and MonarchE

EP: 4.Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

EP: 5.Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

Now Viewing

EP: 6.Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

EP: 7.Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

EP: 8.Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

EP: 9.Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

EP: 10.How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

EP: 11.Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

EP: 12.Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

EP: 13.ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Video content above is prompted by the following question(s):

• In the monarchE and NATALEE trials, the endocrine therapy allowed was different. How did the type of endocrine therapy used impact toxicities seen, and how has that translated to your practice when selecting endocrine therapies?